Impact of Antecedent Aspirin Use on Infarct Size, Bleeding and Composite Endpoint in Patients with de Novo Acute
1Bezmialem Foundation University, Faculty of Medicine, Department of Cardiology, Istanbul, Turkey.
Insights
Prior aspirin use in acute myocardial infarction patients was linked to smaller infarct size. Bleeding risk remained similar, suggesting a potential benefit for these patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Investigating the effects of pre-existing aspirin use in patients diagnosed with de novo acute myocardial infarction (MI).
- Assessing the influence of antecedent aspirin on key clinical outcomes including infarct size and bleeding complications.
Purpose of the Study:
- To determine the impact of prior aspirin usage on myocardial infarct size in de novo acute MI patients.
- To evaluate the association between antecedent aspirin use and in-hospital bleeding events and composite clinical endpoints.
Main Methods:
- Prospective cohort study including 562 consecutive de novo acute MI patients.
- Patients categorized into two groups: prior aspirin users (n=212) and non-users (n=350).
- Myocardial infarct size assessed by peak troponin I; bleeding and composite endpoints also evaluated.
Main Results:
- Prior aspirin users exhibited lower peak troponin I levels, indicating smaller infarct size, despite higher GRACE and CRUSADE scores.
- This finding persisted after adjusting for baseline ischemic risk and MI characteristics.
- No significant increase in major or minor bleeding was observed in prior aspirin users, though minimal bleeding was slightly higher but similar after CRUSADE score adjustment.
Conclusions:
- Antecedent aspirin use in de novo acute MI patients is associated with smaller infarct size.
- Bleeding rates were comparable between prior aspirin users and non-users, suggesting a favorable risk-benefit profile.
Background:
The study aimed to evaluate the impact of antecedent aspirin use on infarct size, bleeding and composite endpoint in patients with de novo acute myocardial infarction.
Patients And Methods:
A total of 562 consecutive patients with de novo acute myocardial infarction were included in this prospective cohort study. Patients were assigned into two groups based on presence (n=212) and absence (n=350) of prior aspirin use. Primary endpoint was myocardial infarct size, as estimated by troponin I peak. In-hospital mortality, bleeding and composite clinical endpoint including cardiogenic shock, stroke, in-hospital mortality and major bleeding were also evaluated.
Results:
Although GRACE and CRUSADE scores were higher, troponin I peak was lower in prior aspirin users. This result was maintained after adjustment for baseline ischemic risk profile and other major confounders including MI type and location. Despite high CRUSADE score, there was no increase in major and minor bleeding. Minimal bleeding was higher in antecedent aspirin users. When it was adjusted for the CRUSADE score, a similar risk was reported.
Conclusion:
Patients with de novo acute myocardial infarction using aspirin for primary prevention have an unexpectedly smaller infarct size and similar bleeding rates.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Acute Coronary Syndrome I: Introduction